SG10201501749WA - Methods for administering long-lasting hypoglycemic agents - Google Patents
Methods for administering long-lasting hypoglycemic agentsInfo
- Publication number
- SG10201501749WA SG10201501749WA SG10201501749WA SG10201501749WA SG10201501749WA SG 10201501749W A SG10201501749W A SG 10201501749WA SG 10201501749W A SG10201501749W A SG 10201501749WA SG 10201501749W A SG10201501749W A SG 10201501749WA SG 10201501749W A SG10201501749W A SG 10201501749WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- hypoglycemic agents
- administering long
- lasting hypoglycemic
- lasting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82547206P | 2006-09-13 | 2006-09-13 | |
| US86839106P | 2006-12-04 | 2006-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201501749WA true SG10201501749WA (en) | 2015-05-28 |
Family
ID=39184534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201501749WA SG10201501749WA (en) | 2006-09-13 | 2007-09-12 | Methods for administering long-lasting hypoglycemic agents |
| SG2011063856A SG174770A1 (en) | 2006-09-13 | 2007-09-12 | Methods for administering long-lasting hypoglycemic agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2011063856A SG174770A1 (en) | 2006-09-13 | 2007-09-12 | Methods for administering long-lasting hypoglycemic agents |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8338369B2 (en) |
| EP (1) | EP2073834B1 (en) |
| JP (2) | JP5524620B2 (en) |
| KR (1) | KR101472601B1 (en) |
| CN (1) | CN103705911A (en) |
| AR (1) | AR062775A1 (en) |
| AU (1) | AU2007296499C1 (en) |
| BR (1) | BRPI0716765A8 (en) |
| CA (1) | CA2662622C (en) |
| CL (1) | CL2007002634A1 (en) |
| CR (1) | CR10684A (en) |
| EA (1) | EA017159B1 (en) |
| ES (1) | ES2442869T3 (en) |
| IL (1) | IL197448A (en) |
| JO (1) | JO2945B1 (en) |
| MA (1) | MA30768B1 (en) |
| MX (1) | MX2009002863A (en) |
| MY (1) | MY149911A (en) |
| NO (1) | NO20091266L (en) |
| NZ (1) | NZ575419A (en) |
| PE (2) | PE20121528A1 (en) |
| SG (2) | SG10201501749WA (en) |
| TW (1) | TWI430806B (en) |
| WO (1) | WO2008033888A2 (en) |
| ZA (1) | ZA200901548B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1965823T3 (en) | 2005-11-04 | 2017-08-31 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
| PL2373681T3 (en) * | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Pharmaceutical compositions of albiglutide |
| WO2011140176A1 (en) * | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| EP3326620B1 (en) | 2010-12-16 | 2020-03-04 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid |
| HUE031405T2 (en) | 2011-04-12 | 2017-07-28 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| MY171146A (en) | 2012-03-22 | 2019-09-27 | Novo Nordisk As | Compositions of glp-1 peptides and preparation thereof |
| PT2827845T (en) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
| EP2863895B1 (en) | 2012-06-20 | 2021-04-14 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| BR112015026325A2 (en) * | 2013-05-02 | 2017-07-25 | Novo Nordisk As | oral dosage of glp-1 compounds |
| ES2900744T3 (en) | 2013-05-28 | 2022-03-18 | Takeda Pharmaceuticals Co | peptide compound |
| JP6995042B2 (en) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | Peptide compound |
| KR102647171B1 (en) | 2018-02-02 | 2024-03-15 | 노보 노르디스크 에이/에스 | Solid composition comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| TWI837615B (en) * | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | Incretin analog-containing compositions and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| ES2319936T5 (en) * | 1996-08-08 | 2013-06-24 | Amylin Pharmaceuticals, Inc. | Regulation of gastrointestinal motility |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6380357B2 (en) * | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| CZ2001690A3 (en) * | 1998-08-28 | 2002-04-17 | Eli Lilly And Company | Method for administering insulintropic peptides |
| WO2000069911A1 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| WO2002047716A2 (en) * | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US7144863B2 (en) * | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
| EP1432730A4 (en) * | 2001-08-23 | 2006-10-11 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
| AR036711A1 (en) | 2001-10-05 | 2004-09-29 | Bayer Corp | PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR PHARMACOLOGICAL USE METHODS |
| PL377687A1 (en) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| WO2003059934A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1463751B1 (en) * | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003058203A2 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| EP1594530A4 (en) * | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albumin fusion proteins |
| ES2524916T3 (en) * | 2003-11-12 | 2014-12-15 | Sino-Med International Alliance, Inc. | Heterocyclic boronic acid compounds |
| BRPI0506781B1 (en) * | 2004-01-13 | 2015-06-02 | Asahi Glass Co Ltd | Multilayer laminate and production method thereof |
| EP1729795B1 (en) * | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005120492A1 (en) * | 2004-06-11 | 2005-12-22 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| PL1965823T3 (en) * | 2005-11-04 | 2017-08-31 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
| US20100022457A1 (en) | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
-
2007
- 2007-09-11 TW TW096133808A patent/TWI430806B/en not_active IP Right Cessation
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/en not_active Application Discontinuation
- 2007-09-11 JO JO2007382A patent/JO2945B1/en active
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/en not_active Application Discontinuation
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/en unknown
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/en active Active
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en active Application Filing
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/en not_active Application Discontinuation
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/en active IP Right Grant
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 AR ARP070104049A patent/AR062775A1/en not_active Application Discontinuation
- 2007-09-12 EA EA200970274A patent/EA017159B1/en not_active IP Right Cessation
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/en active Active
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/en active Protection Beyond IP Right Term
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/en active Pending
-
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/en not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/en not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/en unknown
-
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
-
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
-
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1600047I1 (en) | Methods for administering hypoglycemic agents | |
| ZA200901548B (en) | Methods for administering long-lasting hypoglycemic agents | |
| GB0609492D0 (en) | Therapeutic agents | |
| GB0608928D0 (en) | Therapeutic agents | |
| GB0601962D0 (en) | Therapeutic agents | |
| WO2007082127A8 (en) | Combination therapy for long-lasting ckrtm | |
| EP2092892A4 (en) | Ultrasonograph | |
| EP2014237A4 (en) | Ultrasonograph | |
| GB0606287D0 (en) | Syringe | |
| GB0616214D0 (en) | Therapeutic Agents | |
| EP1997436A4 (en) | Ultrasonograph | |
| GB0611152D0 (en) | Therapeutic agents | |
| GB0603926D0 (en) | Syringes | |
| GB0620818D0 (en) | Therapeutic agents | |
| EP2015810A4 (en) | Improved syringe | |
| GB0625783D0 (en) | Medicament | |
| GB0620059D0 (en) | Therapeutic agents | |
| GB0608046D0 (en) | Syringe | |
| EP2060233A4 (en) | Ultrasonograph | |
| GB0609676D0 (en) | Therapeutic agents | |
| GB0615064D0 (en) | Medicament | |
| EP2047804A4 (en) | Ultrasonograph | |
| GB0615814D0 (en) | Medicament | |
| GB0622195D0 (en) | Therapeutic agents | |
| ZA200809732B (en) | Single use syringe |